Bench to bedside

Oxford enjoys a strong research tradition both in local hospital and Health care trusts and the University’s clinical medical departments. Where there are effective links between the two, patients can often benefit from new treatments at an early stage, while young clinicians and researchers learn to exploit new knowledge as it becomes available. In December 2006 the Department of Health’s National Institute for Health Research (NIHR) recognised the extent and excellence of this tradition by establishing a ‘comprehensive’ Biomedical Research Centre (BRC) at Oxford. Four other comprehensive centres were established in the UK at the same time, together with a further six specialist centres. Each has been given substantial funding over five years to ‘translate fundamental biomedical research into clinical research that benefits patients’. 

Connecting scientific disciplines, healthcare professionals and patients to advance medical research and patient treatment

The goal of NIHR, as part of the government’s strategy ‘Best research for best health’, is to make the National Health Service a centre for research focused on improving the care that patients receive. Oxford’s successful application, the work of many individuals across the University and the Oxford Radcliffe Hospitals Trust, could bring in as much as £100 million over five years in capital, training posts and other resources. The Director of the BRC, Professor Alastair Buchan, is a passionate believer in the idea that training, research and the delivery of healthcare all depend on one another. ‘The fundamental principle of the BRC is to connect different scientific disciplines, healthcare professionals and patients to advance medical research and healthcare delivery’, he says. ‘You can come up with solutions in the lab that don’t translate into treatments, or you can get answers from large-scale clinical trials that don’t work in particular individuals. What the BRC is about is conducting proof-of-principle studies in humans, in a hospital setting, taking what we can from the science and conducting research that will help us to avoid using clever interventions that benefit very few.’

Professor Buchan heads Oxford’s Acute Stroke Programme, which brings together researchers and clinicians to tackle one of the UK’s most common causes of death and serious disability. Oxford research, which emphasises that stroke patients need to be treated as fast as possible, has helped to win funds from the UK Clinical Research Collaboration for an Acute Vascular Imaging Centre (AVIC), which will open in 2008 next to the John Radcliffe’s emergency department. The AVIC will both provide patients with a fast assessment of the brain damage caused by their stroke and host research into new techniques of image capture and analysis.

At the Oxford Centre for Clinical Magnetic Resonance Research (OCMR) a volunteer undergoes a cardiac MRI (magnetic resonance imaging) scan. Oxford’s new Biomedical Research Centre brings together researchers, such as those at the OCMR, and clinicians with the aim of delivering more effective treatment to patients.
At the Oxford Centre for Clinical Magnetic Resonance Research (OCMR) a volunteer undergoes a cardiac MRI (magnetic resonance imaging) scan. Oxford’s new Biomedical Research Centre brings together researchers, such as those at the OCMR, and clinicians with the aim of delivering more effective treatment to patients.

Stroke is one of 14 themes that the BRC is targeting for extra support. Diabetes is another: the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) was one of the pioneers in establishing an effective partnership for clinical research and treatment in Oxford. The Centre moved to its symbolically three sided building in 2003, becoming one of the first research groups to leave the labs in the old Radcliffe Infirmary and establish a new identity on what is now being called Oxford’s biomedical campus next to the Churchill Hospital in Headington.

The three sides symbolise the partnership between the University, the hospital trust and industry: the pharmaceutical company Novo Nordisk was a key partner in establishing the new centre. The same building houses research labs as well as a 26-bed in-patient war and a clinic that sees 30,000 out-patients a year. ‘That’s the aim here – not that we should become divorced in what we do in terms of science, although we have to maintain biological research at fairly high levels, but to say “What can we deliver in terms of care for patients?”’ says Professor David Matthews, chairman of OCDEM. Under Professor Rury Holman, the Diabetes Trials Unit’s flagship project, the UK Prospective Diabetes Study, continues to provide evidence on outcomes in patients with Type 2 diabetes, while several more recent studies are evaluating new treatments. Professor Mark McCarthy and his colleagues are developing new genetic approaches that distinguish one patient from another and open up the possibility of treatments individually tailored to subgroups of patients.

Another major theme is cancer, responsible for the deaths o one in four people in the UK. Oxford is well known for Sir Richard Doll’s pioneering studies of the links between smoking and cancer: today, his legacy, the Clinical Trials Service Unit, continues to investigate the epidemiology of the disease as well as conducting large-scale, randomised trials of cancer treatments. Over the past decade, Oxford’s Medical Sciences Division has pursued a strategy of expanding its strengths in cancer research, with the explicit aim of applying new findings in basic biology and clinical trials to improving treatment for the disease.

Continued on page 2 >

Dr Jenny Taylor, Programme Director

Dr Jenny Taylor, Programme Director of the Oxford
Biomedical Research Centre’s Genomics and Pathology Theme. The BRC is using microarray technology to investigate chromosomal anomalies underlying  speech and language disorders. It is hoped that this will improve diagnosis of these conditions and could have an impact on the clinical management of these patients.